STOCK TITAN
  1. Home
  2. Sec-filings
  3. KAPA
  4. [EFFECT] Kairos Pharma, LTD. SEC Filing

[EFFECT] Kairos Pharma, LTD. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 23, 2026 9:00 A.M.
Form: S-3
CIK: 0001962011
Company Name: Kairos Pharma, LTD.
File Number: 333-292686

Source: View Original Filing on SEC EDGAR

KAIROS PHARMA LTD

NYSE:KAPA

View KAPA Stock Overview →

KAPA Rankings

#6314 Ranked by Market Cap
N/A Ranked by Dividends

KAPA Latest News

Mar 2, 2026
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
Feb 26, 2026
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
Jan 20, 2026
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
Dec 17, 2025
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
Nov 4, 2025
Kairos Pharma Provides Shareholder Update

KAPA Latest SEC Filings

Mar 2, 2026
[8-K] Kairos Pharma, LTD. Reports Material Event
Feb 26, 2026
[8-K] Kairos Pharma, LTD. Reports Material Event
Jan 12, 2026
[S-3] Kairos Pharma, LTD. Shelf Registration Statement
Dec 30, 2025
[Form 4] Kairos Pharma, LTD. Insider Trading Activity
Dec 23, 2025
[Form 4] Kairos Pharma, LTD. Insider Trading Activity

KAPA Stock Data

12.70M
12.11M
Biotechnology
Pharmaceutical Preparations
Link
United States
LOS ANGELES